PRESS RELEASES

September 2021 – OncoNano Medicine Announces Expanded Research Collaboration with UT Southwestern Medical Center to Advance Development of New Cancer Therapies

September 2021 – OncoNano Medicine to Present at The World Molecular Imaging Congress

July 2021 – OncoNano Medicine to Present at the 2nd Annual LifeSci Partners Private Company Summer Symposium

June 2021 – OncoNano Medicine Raises ~$50 Million in Series B Financing

March 2021 –OncoNano Awarded $15.4 Million Grant

March 2021 –Publication of ONM-100 Phase 1

February 2021 – Study Reveals Compelling Data for a New Nanoparticle-based Immuno-Therapeutic to Treat Cancer

February 2021 – OncoNano Medicine Announces Martin Driscoll as Chief Executive Officer

November 2020 – OncoNano Announces Positive Preclinical Data for ONM-400 Tumor Specific IL-2 Delivery at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 2020 – OncoNano Announces Positive Clinical Data for Cancer Imaging Agent ONM-100 at The World Molecular Imaging Congress

August 2020 – OncoNano Awarded $9.97 Million Grant from Cancer Prevention and Research Institute of Texas

June 2020 – OncoNano Announces Publication of ONM-100 Phase 1 Data in Nature Communications

November 2019 – OncoNano Announces Presentations at the 2019 SITC Annual Meeting

September 2019 – ONM-100 to be Featured in Presentation at World Molecular Imaging Congress 2019 

August 2019 – OncoNano Awarded $15.4 Million Grant from Cancer Prevention and Research Institute of Texas

July 2019 – OncoNano Closes Additional $23.7 Million in Second Tranche of Series A Financing, Bringing Total Series A Raise to $35.4 Million

May 2019 – OncoNano to Present Poster on First-in-Human Study of pH-Activated Platform for Detection of Solid Tumors During Surgery at 2019 ASCO Annual Meeting

January 2019 – OncoNano Receives Authorization to Proceed from FDA for IND Application and Fast Track Designation for ONM-100, Intraoperative Imaging Agent to Detect Tumors and Metastatic Lymph Nodes That Often Go Undetected During Surgery

December 2018 – OncoNano Announces Completion of Phase 1a Study and Expands into Phase 1b for Intraoperative Imaging Agent to Detect Tumors and Metastatic Lymph Nodes That Often Go Undetected During Surgery

July 2018 – OncoNano Announces Dosing of Patients in Phase 1 Clinical Trial with ONM-100, an Intraoperative Imaging Agent that Targets Tumor Acidosis for the Detection of Solid Tumors

May 2018 – OncoNano Announces $11.7 Million Series A Financing to Support Development of pH-activated Compound Platform for Disease Detection and Treatment